Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of NS-917 in Japanese patients with relapsed or refractory acute myeloid leukemia
jRCT2031210452Phase 1Active, not recruiting
- Sponsor
- Nippon Shinyaku
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of radgocitabine in acute myeloid leukemia (AML) (2 arms), sponsored by Nippon Shinyaku. Primary endpoints: Dose-limiting toxicity and Pharmacokinetics. Started Feb 2022; status: active, not recruiting.
02
Drugs
radgocitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2031210452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210452.